InvestorsHub Logo
Followers 33
Posts 2837
Boards Moderated 2
Alias Born 10/24/2015

Re: jondoeuk post# 6

Friday, 10/02/2020 7:54:12 PM

Friday, October 02, 2020 7:54:12 PM

Post# of 151
For the allo CAR-T product ('personalised' for certain types) I would like them to insert the CAR(s) into the TRAC locus [1], stop rejection [2], use both CD4/CD8 [3] (of the naive plus (stem) central memory phenotype [4-6]), add a cytokine signal [7], screen donors [8], and make sure the cells are polyfunctional [9] for a start.

In addition, make sure the knockouts are designed to try and overcome the TMEs.

Refs:
1 https://www.nature.com/articles/nature21405
2 https://www.sciencedirect.com/science/article/pii/S0065277615000310
3 https://www.nature.com/articles/leu2015247
4 https://www.nature.com/articles/nm.4241
5 https://www.pnas.org/content/106/41/17469
6 https://www.pnas.org/content/102/27/9571
7 https://www.nature.com/articles/nm.4478
8 https://cancerres.aacrjournals.org/content/80/16_Supplement/879
9 https://ashpublications.org/blood/article/132/8/804/39474/Preinfusion-polyfunctional-anti-CD19-chimeric
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NKTX News